Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Determination of doripenem penetration into human prostate tissue and assessment of dosing regimens for prostatitis based on site-specific pharmacokinetic-pharmacodynamic evaluation.

Nakamura K, Ikawa K, Yamada Y, Arakawa M, Zennami K, Nishikawa G, Ikeda K, Morikawa N, Honda N.

J Chemother. 2012 Feb;24(1):32-7. doi: 10.1179/1120009X12Z.0000000007.

PMID:
22546722
2.

Prostatic penetration of meropenem in humans, and dosage considerations for prostatitis based on a site-specific pharmacokinetic/pharmacodynamic evaluation.

Nishikawa G, Ikawa K, Nakamura K, Yamada Y, Zennami K, Mitsui K, Narushima M, Ikeda K, Morikawa N, Sumitomo M.

Int J Antimicrob Agents. 2013 Mar;41(3):267-71. doi: 10.1016/j.ijantimicag.2012.11.001.

PMID:
23313536
3.

Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics.

Kobayashi I, Ikawa K, Nakamura K, Nishikawa G, Kajikawa K, Yoshizawa T, Watanabe M, Kato Y, Zennami K, Kanao K, Tobiume M, Yamada Y, Mitsui K, Narushima M, Morikawa N, Sumitomo M.

J Infect Chemother. 2015 Aug;21(8):575-80. doi: 10.1016/j.jiac.2015.04.015.

PMID:
26050020
4.

Penetration of doripenem into prostatic tissue following intravenous administration in prostatectomy patients.

Yamada Y, Ikawa K, Nakamura K, Mitsui K, Narushima M, Hibi H, Ikeda K, Morikawa N, Honda N.

Int J Antimicrob Agents. 2010 May;35(5):504-6. doi: 10.1016/j.ijantimicag.2010.01.008.

PMID:
20188521
5.

Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.

Samtani MN, Flamm R, Kaniga K, Nandy P.

Antimicrob Agents Chemother. 2010 Jun;54(6):2360-4. doi: 10.1128/AAC.01843-09.

6.

Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients.

Ikawa K, Morikawa N, Uehara S, Monden K, Yamada Y, Honda N, Kumon H.

Int J Antimicrob Agents. 2009 Mar;33(3):276-9. doi: 10.1016/j.ijantimicag.2008.08.031.

PMID:
19095418
8.

Pharmacodynamic assessment of doripenem in peritoneal fluid against Gram-negative organisms: use of population pharmacokinetic modeling and Monte Carlo simulation.

Ikawa K, Morikawa N, Ikeda K, Ohge H, Sueda T.

Diagn Microbiol Infect Dis. 2008 Nov;62(3):292-7. doi: 10.1016/j.diagmicrobio.2008.06.016.

PMID:
18703305
9.

Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients.

Kays MB, Fleming MR, Cheatham SC, Chung EK, Juenke JM.

Ann Pharmacother. 2014 Feb;48(2):178-86. doi: 10.1177/1060028013512474.

PMID:
24259653
10.

Pharmacokinetics and monte carlo simulations of doripenem in patients with febrile neutropenia.

Stein GE, Kulhanek G, Smith CL, Kuti JL, Nicolau DP, Scharmen A, Farnum C, Tran M, Kalra A, Havlichek DH.

Ann Pharmacother. 2012 Oct;46(10):1281-6. doi: 10.1345/aph.1R097.

PMID:
23012385
11.

Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.

Villegas MV, Briceno DF, Ruiz SJ, Furtado GH, Nicolau DP.

Braz J Infect Dis. 2011 Sep-Oct;15(5):413-9.

12.

Pharmacokinetics of doripenem in infected patients treated within and outside the intensive care unit.

Bhalodi AA, Keel RA, Quintiliani R, Lodise TP, Nicolau DP, Kuti JL.

Ann Pharmacother. 2013 May;47(5):617-27. doi: 10.1345/aph.1R789.

PMID:
23585647
13.

When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.

Goff DA, Nicolau DP.

Clin Ther. 2013 Jun;35(6):766-71. doi: 10.1016/j.clinthera.2013.05.004.

PMID:
23795574
14.

Pharmacokinetic analysis of doripenem in elderly patients with nosocomial pneumonia.

Harada M, Inui N, Suda T, Nakamura Y, Wajima T, Matsuo Y, Chida K.

Int J Antimicrob Agents. 2013 Aug;42(2):149-54. doi: 10.1016/j.ijantimicag.2013.03.012.

PMID:
23684002
15.

Pharmacokinetic/pharmacodynamic modeling and simulation to determine effective dosage regimens for doripenem.

Katsube T, Yano Y, Wajima T, Yamano Y, Takano M.

J Pharm Sci. 2010 May;99(5):2483-91. doi: 10.1002/jps.21997.

PMID:
19904828
16.

In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures.

Kim A, Banevicius MA, Nicolau DP.

Antimicrob Agents Chemother. 2008 Jul;52(7):2497-502. doi: 10.1128/AAC.01252-07.

17.
18.

Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region.

Roberts JA, Kwa A, Montakantikul P, Gomersall C, Kuti JL, Nicolau DP.

Int J Antimicrob Agents. 2011 Mar;37(3):225-9. doi: 10.1016/j.ijantimicag.2010.10.024.

PMID:
21168997
19.

Development of breakpoints of carbapenems for intraabdominal infections based on pharmacokinetics and pharmacodynamics in peritoneal fluid.

Ikawa K, Morikawa N, Ikeda K, Ohge H, Sueda T.

J Infect Chemother. 2008 Aug;14(4):330-2. doi: 10.1007/s10156-008-0624-1.

PMID:
18709540
20.

Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region.

Kiratisin P, Keel RA, Nicolau DP.

Int J Antimicrob Agents. 2013 Jan;41(1):47-51. doi: 10.1016/j.ijantimicag.2012.09.007.

PMID:
23127484
Items per page

Supplemental Content

Support Center